Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis.
about
Intravenously administered vitamin C as cancer therapy: three casesSaudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladderRisk based neoadjuvant chemotherapy in muscle invasive bladder cancerRole of systemic chemotherapy in urothelial urinary bladder cancerMultimodal management of muscle-invasive bladder cancerTargeting Hsp90 in urothelial carcinomaAdjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?Outcome of urinary bladder cancer after combined therapiesPooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancerRefining patient selection for neoadjuvant chemotherapy before radical cystectomyThe role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidenceAdjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials.Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity.Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guidelineSaudi oncology society and Saudi urology association combined clinical management guidelines for urothelial urinary bladder cancer.Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.Saudi Oncology Society clinical management guidelines for urinary bladder cancer.Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder.Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapyTrends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancerDisease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: External Evaluation and Validation in a CohortNeoadjuvant chemotherapy in invasive bladder cancer.Recent advances in the treatment of bladder cancer.Developing innovative strategies for advanced transitional cell carcinoma of the bladder.Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.Nonplatinum therapy in advanced bladder cancer.Adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: updated results of the Seoul National University Hospital experienceNeoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion.Presurgical therapy in metastatic renal cell carcinoma.Efficiency of study designs in diagnostic randomized clinical trials.Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder?Outcome of urinary bladder cancer after combined therapies.Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy.Treatment of locally advanced and metastatic bladder cancerThe efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma.Optimizing care and outcomes of patients with muscle-invasive bladder cancer.
P2860
Q24540524-2BA9EA94-F999-4549-B897-0245D0D3B108Q26747775-7A12D3B1-D7FD-4483-8D44-09ABF4ABD472Q26773664-6D11F28D-C3C3-435B-8D31-151DA97AD439Q27010323-0189D3E6-0D8B-4511-B191-237791FCEAE3Q27011624-66D048C7-C7D3-4884-9BD4-89F1D6EFC776Q27023406-06662778-E726-4892-A3AD-502EF6D7E334Q28066214-C88593EB-B874-4164-A05E-2D962D4217C6Q28076180-967F29C3-FEAB-4A46-87EC-85DF42C38E67Q28278664-5D1292F6-CC3F-4787-A4AF-F0215870D8F8Q30408866-2851DAF4-910A-4A10-83F4-44E32DB12528Q30845020-918E3A41-5DCE-4AD5-B860-72A24690A95EQ33396809-8D40E884-D4E2-4766-A9DA-572FDEF205C3Q33433507-CE27380B-DC57-45D6-9D28-6BE423139BEBQ33662842-D84DA2AC-5A6D-43F3-9DCD-9090DD4289A0Q33670824-D641C26D-8C54-425E-90B3-AD1F285D5F13Q34023055-D06E9DAC-2640-4C10-8F54-C94188F0A4D7Q34437299-5D07A5DF-E547-490A-800F-484B605A9A58Q34993621-5846A701-134F-4B63-9337-328EA52D0E65Q34997367-2C45FABA-4050-4D1F-8749-37471DE4B541Q35125750-B8C0BBEE-DA80-4EDF-8042-172BDA559E01Q35667815-73765B6E-9F72-499E-A8ED-B24F9B7B2140Q35748071-0559641C-2A29-42D1-B2FC-21BE4ADCC869Q36099310-0FB4E15D-1D98-4CEA-A664-BC5C96D09127Q36221402-FC7F889E-9A95-42B5-A2F4-A196CC069846Q36334882-2A8D2F0C-2C6A-420A-83EE-E143CD6BD226Q36334892-C6B2FC37-546E-41B0-A034-4828DBA3EDFBQ36352085-F043E704-D805-44C4-AA77-4AB6BEA74F28Q36381303-FBEAF314-C086-4089-9B01-1D1FB3F15B7DQ36500541-69CA3CA7-E68A-4456-BC76-9712755928B5Q36589221-9BD3E7F0-6582-4202-9B48-1CBD7BFF20A1Q36628852-0AE7FD1E-6638-410F-A059-6F22DB8C1632Q36691815-40668BC0-6D3D-49DA-8CA2-7BCF357ADCFEQ36692628-C27C65D0-3468-448C-B644-6CDA4A5446FAQ36808415-27ACE426-F6BA-4EE1-BC34-EF130791E29FQ36890974-CCD5F3DF-5F48-4AB2-AE69-8EA11BF3F5C4Q37025948-9BDAF6C3-0A15-4E14-9D89-0D07ECFF1AC2Q37171971-26CCE790-7B0E-4CE3-8FAF-DB01F03A25D4Q37197514-7853AEE2-3C13-4E97-8627-BEA816AAD6BDQ37249515-CFB9D51E-E1A8-4052-ABD2-9E3730D6C396Q37455252-E067BA79-9675-4F80-8E1D-60116E58651B
P2860
Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Neoadjuvant chemotherapy for t ...... atic review and meta-analysis.
@ast
Neoadjuvant chemotherapy for t ...... atic review and meta-analysis.
@en
type
label
Neoadjuvant chemotherapy for t ...... atic review and meta-analysis.
@ast
Neoadjuvant chemotherapy for t ...... atic review and meta-analysis.
@en
prefLabel
Neoadjuvant chemotherapy for t ...... atic review and meta-analysis.
@ast
Neoadjuvant chemotherapy for t ...... atic review and meta-analysis.
@en
P2093
P31
P1476
Neoadjuvant chemotherapy for t ...... atic review and meta-analysis.
@en
P2093
Eric Winquist
Genitourinary Cancer Disease S ...... Practice Guidelines Initiative
Himu Lukka
Joseph Chin
Roanne Segal
Tricia S Kirchner
P304
P356
10.1097/01.JU.0000090967.08622.33
P407
P433
P577
2004-02-01T00:00:00Z